Wnt-b-catenin-T-cell factor signaling is causally linked to c-myc-dependent tumorigenesis in mouse and human colon epithelial cells. By contrast, b-catenin is not similarly associated with oncogenic transformation of other tissues, including T cells. The molecular basis for tissue specificity of b-catenin-dependent oncogenesis is unknown. Here, we demonstrate that adenomatous polyposis coli mutant APC Min/ þ mice, which have increased expression of b-catenin in all tissues, develop severe intestinal neoplasia, but fail to develop thymic lymphoma. Whereas b-catenin-dependent signals elicit a proliferative response from intestinal cells, thymocytes experience oncogene-induced senescence (OIS), growth arrest and apoptosis. We demonstrate that the differential cellular response of thymocytes and intestinal epithelial cells is a direct consequence of the gene expression elicited by b-catenin expression in each tissue. We find that whereas intestinal cells induce genes that promote proliferation thymocytes induce expression of genes associated with OIS, growth arrest and p53-dependent apoptosis. We correlate gene expression pattern with the role b-catenin plays in the development of each tissue and suggest that susceptibility of transformation by b-catenin is intimately related to its function during development. We propose that when oncogenes are used as signaling molecules, safety nets in the form of OIS, growth arrest and apoptosis prevent accidental transformation.
INTRODUCTION
The canonical Wnt-b-catenin-T-cell factor (TCF) signaling pathway plays an essential role in maintaining the intestine by providing proliferative signals to precursor stem cells. 1 Impairment of this signaling pathway results in a severe loss of the proliferative progenitors of the prospective crypts in fetal and adult intestine. [2] [3] [4] By contrast, aberrant activation of this pathway due to mutations in adenomatous polyposis coli (APC), a tumor suppressor gene that is inactivated in most colorectal cancers, induces hyperproliferation of the intestinal epithelium and results in cancer. [5] [6] [7] Specifically, TCF4 and b-catenin target gene, c-Myc, is causative in promoting colon cancer, 8, 9 whereas target gene TCF1 behaves as tumor suppressor in this model. 10 As Wnt-signaling pathway is required for T-cell development and function, it might be expected to induce lymphomagenesis but few examples of this are currently reported. As a matter of fact, it has been previously noted that b-catenin-TCF1-signaling pathway may not be causally linked with human T-cell lymphomas. [11] [12] [13] Furthermore, analysis of AML (acute myeloid leukemia) and ALL (acute lymphoblastic leukemia) showed that these cancers were distinguishable based on the expression of b-catenin, with AML cells expressing higher levels compared with ALL cells. 14 In other examples of transformed human T cells, noticeable b-catenin accumulation was correlated with reduced expression of TCF1, indicating that TCF1 and b-catenin-dependent transcription may not be a major contributor to T-cell cancer. 15, 16 This contrast in the ability of bcatenin to transform intestinal cells, but not T cells, is of particular interest because both cell types utilize Wnt-b-catenin-TCFsignaling pathway for tissue renewal throughout the life of the organism. 17 Whereas intestinal cells utilize b-catenin signals for proliferation in response to a Wnt gradient, b-catenin expression regulates T-cell development. [18] [19] [20] [21] Specifically, we have shown that developmental signals transiently induce b-catenin expression in immature thymocytes, which is required to be turned down for proper T-cell development. [22] [23] [24] In a mouse model with transgenic expression of oncogenic b-catenin in thymocytes from the proximal Lck promoter, failure to turndown b-catenin expression results in developmental block. 23 Developmentally blocked thymocytes induce genes that regulate oncogene-induced senescence (OIS), growth arrest and p53-dependent apoptosis, resulting in a hypocellular thymus. This cellular response also protects thymocytes from transformation, which is permitted when p53 function is removed as thymocytes expressing oncogenic b-catenin fail to undergo p53-dependent apoptosis. 24 These observations show that developing intestinal cells and immature thymocytes exhibit distinct response to expression of b-catenin. However, the molecular basis for transformation of intestinal cells, but not thymocytes, in response to b-catenin expression remains unknown.
In this report, we provide a molecular basis for the tissue specificity of b-catenin-dependent oncogenesis. We demonstrate that the differential cellular response of thymocytes and intestinal epithelial cells is a direct consequence of the gene expression elicited by b-catenin expression in each tissue. We find that whereas Min intestinal cells induce genes that promote proliferation thymocytes induce expression of genes associated with OIS, growth arrest and p53-dependent apoptosis. We correlate gene expression pattern with the role b-catenin plays in the development of each tissue. Our data suggest that susceptibility of transformation by b-catenin is intimately related to its function during development. In light of these observations, we propose that oncogenesis is regulated by the response of the cell type to expression of the oncogene, which in turn is congruent with the role of the oncogene as a signaling molecule in the development of the tissue.
RESULTS

Min intestinal cells and Min thymocytes respond distinctly to enhanced b-catenin expression
To address directly the molecular basis for distinct response of the intestinal tissue and thymocytes to b-catenin expression, we have utilized APC Min/ þ (Min) mouse model. Min mice bear a heterozygous germ line mutation at codon 850 of the APC gene and consequently overexpress endogenous b-catenin in all tissues. [25] [26] [27] Min mice develop adenomatous polyps 28 (and Figure 1a) . By contrast, Min mice have small dramatically hypocellular thymuses (Figures 1b and c) . These data show that the response of thymus and intestinal tissue to overexpression of b-catenin is dramatically distinct.
We found that relative abundance of b-catenin protein in control thymocytes was lower than in control intestinal tissue (Figure 1d ). Accordingly, expression of Wnt target genes in the control intestinal tissue was approximately twofold higher than in thymocytes ( Figure 1e ). Min thymocytes and intestinal tissues showed increased b-catenin expression compared with control tissues (Figure 1d ). Therefore, Min thymocytes and Min gut polyps showed increased expression of target genes such as Axin2, c-jun and c-fos compared with control thymocytes and gut ( Figure 1e ). These data demonstrate that increased b-catenin expression correlated with an increase in b-catenin-dependent gene expression in both thymocytes as well as intestinal tissue. However, despite increase in b-catenin-dependent signaling in Min thymocytes, these mice failed to develop thymic lymphoma. Min mice are known to undergo loss of the wild-type (WT) Apc allele in intestinal epithelium. 29 Therefore, we assayed for the status of the Apc alleles in Min thymocytes and found that in the Min thymocytes one allele was WT and one allele was mutant (Figure 1f ). To determine if the lack of thymic lymphoma correlated with changes in cell death or proliferative status, we stained ex-vivo thymocytes with AnnexinV and studied BrdU uptake in vivo. We found that Min thymocytes had increased apoptosis ( Figure 1g ) and reduced proliferation (Figure 1h ). Thus, increased expression of b-catenin induces apoptosis and growth arrest in developing thymocytes, which results in small hypocellular thymuses in Min mice.
Thymocyte development is stalled in Min mice Thymocyte development is defined based on the expression of cell-surface markers CD4 and CD8, with the most immature thymocytes lacking these markers. The immature CD4
À and CD8 À double-negative (DN) thymocyte population can be further dissected into developing subsets using cell-surface expression of c-kit and CD25 (ETP:c-kit
. 30 We found that Min thymocytes were blocked at the DN4/pre-DP stage of development (Figures 2a-c) . DN4/pre-DP Min thymocytes expressed intracellular T-cell receptor b chain (TCRb IC ), which identifies developmentally competent DN4 thymocytes (Figure 2d ). TCRa chain is expressed in DP thymocytes following TCRb chain expression. We found that Min-pre-DP thymocytes did not express cell-surface TCRa (Figure 2e ). The lack of TCRa chain expression confirmed that these stalled thymocytes were attenuated in development at the pre-DP stage. Molecular features of developmentally stalled Min pre-DP thymocytes showed a higher abundance of Egr 1, 2, and 3, which indicates that these thymocytes have received pre-T-cell receptor signals (Figure 2f ). However, further development is blocked at the DN4/pre-DP stage as the stalled thymocytes express low levels of Rorgt compared with control DN4 cells (Figure 2f ). These data demonstrate that stalled thymocytes had failed to extinguish pre-TCR signals (represented by higher expression of Egr proteins) and to induce transcription factor RORt, which is required for transition to the DP stage, which is consistent with previously described block at the DN4/pre-DP stage upon thymocyte-specific loss of the APC gene. 31 Thus, failure to downregulate expression of b-catenin past the pre-DP/DN4 stage blocks thymocyte development to the DP stage.
To confirm that the developmental block resulted from cellintrinsic overexpression of b-catenin, we studied T-cell development in mice that express transgenic b-catenin from the Lck proximal promoter in developing thymocytes (CAT-Tg mice). 32 CAT-Tg mice show an increase in DN cells, which are blocked at DN4/pre-DP stage (Supplementary Figure 1) , and have higher expression of Egr 1, 2, and 3, and lower expression of Rorgt (Supplementary Figure 2) . These data show that Min thymocytes share several features with CAT-Tg thymocytes and thereby demonstrate that thymic hypocellularity in Min mice was not a result of the intestinal tumors as intestinal cells do not overexpress b-catenin in CAT-Tg mice and the intestine is healthy. Finally, we note that even in Min mice adenoma count was comparable in mice with normal or low thymocyte count (60 ± 3 and 68 ± 4, respectively). These data confirm a lack of any connection between adenoma and thymic cellularity (Supplementary Figure 3) . Together, these data demonstrate that cell-intrinsic expression of b-catenin leads to a developmental block in T-cell development in Min mice.
Differential gene expression in Min hypocellular thymus and intestinal cells is the basis for tissue specificity of b-catenin oncogenesis Next, we addressed the molecular basis for tissue-specific oncogenic function of b-catenin by studying gene expression in thymocytes and intestinal epithelial cells obtained from control and Min mice. We have previously reported that cell-intrinsic expression of b-catenin in DN4-pre-DP thymocytes induces expression of genes associated with growth arrest, OIS and apoptosis. 24 Stalled Min pre-DP/DN4 thymocytes induced expression of these genes (Figure 3a) , including genes associated with p53-dependent apoptosis ( Figure 3b ). To confirm that induction of these genes was in response to increased expression of b-catenin, we analyzed thymocytes from CAT-Tg mice. We found that CAT-Tg DN4 thymocytes also showed increased expression of genes linked with growth arrest, OIS and apoptosis (Supplementary Figure 4) . These results demonstrate that bcatenin overexpression in thymocytes (driven by mutation in the APC gene or as b-catenin transgene) induces genes associated with growth arrest, OIS and apoptosis. In striking contrast, genes associated with growth arrest, OIS and apoptosis were not induced, instead were sometimes suppressed, in the intestinal adenomatous polyps (Figures 3c and d) , which is consistent with the proliferative response elicited by increased expression of bcatenin in these cells. These data demonstrate that the molecular response of thymocytes and intestinal epithelial cells to overexpression of oncogenic b-catenin is very disparate and matches the distinct cellular responses.
p53-Dependent apoptosis protects Min mice from thymic lymphoma The induction of growth arrest, OIS and apoptosis genes in response to b-catenin expression in thymocytes is very likely the reason for the absence of b-catenin-dependent thymic lymphomas. Growth arrest, OIS and apoptosis have all been shown to be p53-dependent under various conditions. 33 To directly test the role of p53 in Min mice, we generated p53-deficient Min mice. We found (data not shown), as has been previously reported, 34 that rate of adenoma formation and progression to malignancy in p53 À / À Min mice was similar to Min mice. In sharp contrast, the Regulation of tissue specificity of b-catenin oncogenesis A Sharma and JM Sen All results are presented relative to the abundance of GAPDH. *Pp0.05; **Pp0.005; ***Pp0.0005; ns ¼ not significant; Student's t-test. Data are pooled from two to three independent experiments with a total of four to eight independent samples (error bars, s.e.m.).
Regulation of tissue specificity of b-catenin oncogenesis A Sharma and JM Sen metastatic potential of the transformed thymocytes. p53 À / À Min DN thymocytes showed increased expression of OIS-associated genes like p15 and Dec1 and other cell cycle inhibitors (Figure 4d ). However, we note that expression of the cell cycle inhibitor p21 was decreased in p53 À / À Min DN lymphoma cells, which correlates with increased proliferation (Figure 4d ). The number of thymocytes was also significantly increased in p53 À / À Min compared with extremely hypocellular Min thymus (Figure 4e ), which indicates thymocyte proliferation. The increased cell death observed in Min DN4 thymocytes compared with control DN4 thymocytes was abrogated in p53 À / À Min DN4 thymocytes (Figure 4f ). These data are congruent with our previous report showing p53-independent b-catenin-induced OIS and growth arrest and p53-dependent apoptosis in p53 À / À CAT-Tg thymic lymphoma. 24 These data show that increased expression of bcatenin (endogenous or enforced) promotes thymic lymphoma when p53 function is removed. Further analysis showed that similar to Min thymocytes, thymic lymphoma cells in p53 À / À Min mice have increased b-catenin protein expression (Figure 4g ) and increased expression of target genes (Figure 4h) . Analysis of the status of the Apc alleles in p53 À / À Min thymic lymphoma showed the presence of both WT and mutant Apc alleles (Figure 4i ).
Together, these data show that p53-dependent apoptosis plays a critical role in protecting thymocytes, but not intestinal cells, from b-catenin-dependent transformation.
Molecular basis for the formation of intestinal polyp and thymic lymphoma are distinct Gene expression analysis shows that intestinal polyps express high levels of c-Myc (Figure 5a ), which along with other signals that promote proliferation and polyp formation. By contrast, immature Min thymocytes do not induce expression of c-Myc in response to b-catenin expression even in the absence of p53 when they develop into lymphoma (Figure 5b ). Because Notch signaling has been implicated in thymic lymphomagenesis, we assayed for the expression of Notch target genes, Dtx1 and Hes1. Neither gene was upregulated in p53-deficient Min lymphoma cells (Figure 5b ). These data suggest that b-catenin-dependent lymphoma in p53-deficient immature thymocytes was not due to c-myc or Notchdependent signals. We conclude that in addition to initial response to b-catenin expression being tissue specific, the molecular basis for the oncogenic function of b-catenin is distinct in each cell type. We note that these responses are congruent with the role played by b-catenin in the development of each tissue. In light of these data, we propose that oncogenesis is regulated by the molecular and cellular response of the tissue in which it is expressed, which in turn is congruent with the signaling role played by the oncogene in the development and maintenance of that tissue. The distinct tissue-specific response to a ubiquitously expressed oncogene provides a plausible explanation for the tissue specificity of oncogenesis. In this report, we provide evidence that b-catenin expression in intestinal tissue induces gene expression congruent with proliferative response whereas in thymocytes genes associated with OIS, growth arrest and apoptosis are induced. A previous report showed that loss of Apc in renal epithelium led to accumulation of b-catenin and rapid development of renal carcinoma, which is further accelerated by p53 deficiency. 35 Interestingly, a subsequent study from the same group showed that Apc loss from the renal and intestinal epithelium resulted in OIS in renal cells but not in intestinal cells, with a double loss of p21 and Apc, resulting in rapid renal carcinoma. 36 Tissue-specific regulation of p19 Arf has been shown to dictate response to oncogenic K-ras. 37 These studies are congruent with the notion that protective mechanisms including OIS and p21-dependent growth arrest provide built-in protective mechanisms in tissues that use oncogenes as signaling agents. In addition to differential gene expression to the initial expression of b-catenin, molecular basis for transformation is also distinct in different tissues. In contrast to intestinal cells, p53-deficient immature thymocytes did not respond to b-catenin expression by inducing expression of c-myc. As a matter of fact, expression of Dtx1 and Hes1, which are associated with thymic lymphoma, was also not induced. These data suggest that neither c-myc nor Notch signaling was induced in stalled p53-deficient Min thymocytes. Differential function of c-myc in b-catenin-dependent transformation of different tissues has been reported previously. 38 In light of the above observations we propose that in addition to initiation of transformation, which results from tissue-specific response to oncogene expression, molecular basis of transformation by an oncogene is also tissue-specific.
We note that lack of a causal connection between oncogene b-catenin and T-cell lymphoma is not due to paucity of research in this area. The search for a role for the Wnt-b-catenin-TCF1 pathway in T-cell lymphoma began with the original observation from the Clevers laboratory that TCF1 was expressed in T cells but not in B cells. 39 This report was followed by observations that bcatenin was highly expressed in some human T-ALL cell lines such as Jurkat, 40, 41 but TCF1-dependent transcription activation could not be demonstrated in Jurkat cells. 42, 43 More recent reports have provided a mixed picture of b-catenin expression in human ALL cells, with a fraction of cells also showing Exon3 mutations that might result in b-catenin accumulation. 44 However, it remains to be demonstrated that accumulated b-catenin leads to increased function of TCF1-dependent gene expression, which causally result in thymic lymphoma. This is not surprising in light of the observation that several molecular manipulations that lead to increased b-catenin accumulation in developing thymocytes result in a developmental block and thymic atrophy. 20, 23, 24, 31, 45, 46 We propose that it is the induction of OIS, growth arrest and apoptosis in developing thymocytes in response to b-catenin that results in the absence of causal connection between T-cell transformation and b-catenin overexpression. In addition, we suggest that constitutive and high level of TCF1 expression in thymocytes might function as a built-in tumor suppressor and protect from lymphomagenesis.
These data support a model in which, during normal intestinal renewal, intestinal precursor cells induce b-catenin in response to a Wnt gradient to promote proliferation. 8, 47 As the developing cells migrate away from the crypt, Wnt gradient diminishes leading to decrease in proliferation, which allows for controlled expression of b-catenin to regulate cellularity. However, in the intestine abnormal induction of b-catenin due to mutations in the genes of the Wnt-b-catenin-TCF4 pathway results in uncontrolled proliferation 8 and (Supplementary Figure 5a) . By contrast, in thymocytes b-catenin is induced transiently and provides signals for maturation and then thymocytes must turn the protein expression down for further development ( Supplementary  Figure 5b) . Failure to turndown expression of b-catenin during maturation leads to a developmental block in thymocytes at the pre-DP stage. 22, 23 The developmentally stalled thymocytes experience additional events, become pre-cancerous and experience OIS. We have also found that stalled cells are growth arrested and are then removed from the developmental pool by p53-dependent apoptosis thereby protecting developing T cells from b-catenin-dependent oncogenesis. 24 Importantly, this protective response is strictly restricted to the immature thymocytes that utilize b-catenin for maturational signals. Overexpression of b-catenin using CD4 À Cre-dependent deletion of exon 3 that induces b-catenin stabilization in more mature CD4 þ CD8 þ DP thymocytes supported c-myc-dependent oncogenesis. 48 Because DP thymocytes normally do not express bcatenin, we propose that ectopic expression of b-catenin induces c-myc and potentially other targets genes in DP thymocytes, which then supports transformation as there are no inherent mechanisms of protection. Alternately, b-catenin protein level may regulate extent of Wnt-related signaling and c-myc expression as dose of Wnt signaling has been correlated with gene expression. 49 In light of these observations, we suggest that oncogenic function of b-catenin is orchestrated by the tissuespecific response of the cells and intimately related to the role it plays in the development of the tissue. We propose that when oncogenes are used to provide developmental signals 'safety nets' comprising of OIS, growth arrest and apoptosis are put in place to prevent oncogenesis.
In conclusion, tissue specificity of oncogenesis is defined by tumors being confined to a few tissues despite expression of oncogenes in multiple tissues. Data provided in this paper provide a novel perspective on the molecular basis for the difference in the response of intestinal epithelial cells and thymocytes to b-catenin expression and the disparate outcomes. Based on the data presented in this paper, we propose that the oncogenic function of b-catenin is intimately related to the role it plays in the development of the particular tissue. Finally, as inhibitors of b-catenin pathway, [50] [51] [52] and inducers of p53 function 53, 54 have been defined and are available for use in clinical situations, these observations provide new opportunities for designing tissuespecific therapeutic strategies for treating the human cancers.
MATERIALS AND METHODS Mice
APC
Min/ þ (Min) mice and p53 À / À mice are on a C57BL/6 genetic background and were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The generation of CAT-Tg and p53
À / À CAT-Tg mice has been described previously. 24, 32 p53 À / À Min were generated by crossing p53 À / À mice with Min mice. Age-matched littermate control mice or C57BL/6 mice were used in all experiments. All mice were bred and maintained in the animal facility of the National Institute on Aging according to the regulations of the National Institutes of Health and were in compliance with the guidelines of the animal resources facility of the National Institute on Aging, which operates under the regulatory requirements of the US Department of Agriculture and Association for Assessment and Accreditation of Laboratory Animal Care.
Western blot analysis
Immunoblotting was performed with whole-cell lysates resolved on 4-12% Bis-Tris sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and detected using Abs against mouse b-catenin (14/Beta-Catenin; 610154; BD Pharmingen, San Jose, CA, USA) or rabbit-anti-PKC-m (C-20; sc-639; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by horseradish peroxidase-conjugated anti-mouse IgG (sc-2005) or anti-rabbit IgG (sc-2004; both from Santa Cruz). Reactivity was visualized by enhanced chemiluminescence.
Allele-specific APC genomic PCR analysis
The Min mutation was identified by allele-specific PCR done as per Jackson Laboratory protocol. Briefly, the mutant Min primer (5 0 -TTCTGAGAAAGA CAGAAGTTA-3 0 ), whose 3 0 -most nucleotide is complementary to the Min nonsense mutation at nucleotide 2549 of Apc, and the primer MAPC 15 (5 0 -TTCCACTTTGGCATAAGGC-3 0 ) is used in PCR. A PCR product of B340 bp is generated in the presence of the Min allele, but no product is generated in its absence. As an internal positive control for the PCR, a third primer, MAPC 9 (5 0 -GCCATCCCTTCACGTTAG-3 0 ) was included in the reaction. MAPC 9 and MAPC 15 together generate a 618-bp product surrounding the Min nonsense mutation detected in WT and APC Min/ þ .
Antibodies and flow cytometry
Cells were collected, stained and analyzed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA). Dead cells were excluded by assessing forward light scatter data. All the data were acquired and are presented on a log scale. The following antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein-cyanine 5.5, allophycocyanin or biotin (all from BD Pharmingen) were used for staining: anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-CD25 (PC61), anti-c-Kit (2B8), antiTCRb (H57-597), anti-TCRgd (GL3), anti-B220 (RA3-6B2), anti-Gr-1 (RB6-8C5), anti-Mac-1 (M1/70), anti-NK1.1 (PK136), anti-Ter119 (Ter119), anti-TCRVa 2 (B20.1), TCRVa 3.2 (RR3-16), TCRVa 8.3 (B21.14) and TCRVa 11.2 (RR8-1). Lineage-specific cocktail contained antibodies to CD4, CD8, TCRb, TCRgd, B220, NK1.1, Gr1 and Mac-1. For DN purification, cell suspensions of thymocytes were stained with biotinylated anti-CD4 and anti-CD8, followed by incubation with anti-biotin microbeads (Miltenyi Biotec, Auburn, CA, USA) and magnetic depletion of DP and SP thymocytes. DN enriched cell suspensions were surface stained with lineage Ab mixture, anti-CD25 and anti-c-kit, followed by sorting using MoFlo (Beckman Coulter, Miami, FL, USA). To assess apoptosis, freshly isolated thymocytes were first stained with surface markers, followed by staining with fluorescein isothiocyanate-conjugated annexin V (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions.
In-vivo BrdU incorporation assay
BrdU flow kit (BD Pharmingen) was used for proliferation assay. Briefly, 100 ml of 10 mg/ml of the BrdU solution was injected intraperitoneally. BrdU incorporation was assayed 2 h post-injection. Thymocytes were first stained with surface markers and followed by intracellular staining with anti-BrdU antibody conjugate.
Isolation of intestinal adenomas
WT control and Min mice were killed at the age of 4 months and whole intestinal rolls were removed; the lumenal contents were flushed out with PBS (phosphate-buffered saline), the tissue was slit open longitudinally and laid flat mucosal surface up. Adenomatous polps were counted and scored visually, then intestine was chopped into B5 cm or smaller pieces and the fragments were washed three times in cold PBS. Polyps were carefully dissected to exclude non-adenomatous tissue and homogenized in lysis buffer (Qiagen, Hilden, Germany).
Real-Time RT-PCR mRNA was extracted from sorted DN4 thymocytes and intestinal tissue using RNeasy Micro Kit (Qiagen). Total mRNA was reversed transcribed into cDNA with poly(dT) and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). SYBR green quantitative real-time RT-PCR (reverse transcriptase polymerase chain reaction) was performed, using PCR Master Mix (Applied Biosystems, Foster City, CA, USA), for 40 cycles with annealing and extension at 60 1C (primer sequences; Supplementary Table 1 ). The expression of target gene was determined relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and calculated as 2 À (CtTarget gene À CtGAPDH) .
